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in 10% of patients with vitreous haemorrhage average cost of which was 10% of 
616EUR/operation. It was assumed that surgical treatment (trabeculectomy, Seton 
operation or cyclophotocoagulation) was applied in 2% of increased ocular pres-
sure (IOP) patients average cost of which was 196EUR/operation. Pharmacologic 
treatment was assumed to be applied in 98% of the IOP patients cost of which 
was 4EUR/patient. Thus, overall cost of IOP was calculated as 8EUR. The cost of 
arterial thromboembolic events (282EUR) was taken from local sources. The total 
CoD was calculated as 5520EUR in patients treated with ranibizumab where the 
total cost excluding pharmaceutical was estimated as 590EUR (administration cost 
121EUR, monitoring cost 442EUR, adverse event cost 27EUR). ConClusions: In 
DME, the main part of total CoD was consisted of costs of the treatment, followed 
by monitoring costs.
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objeCtives: The introduction of treatment with inhibitors of Vascular Endothelial 
Growth Factor (VEGF) has made possible the treatment of the Retinal Vascular 
Diseases (RVD) for which there was limited therapeutic resources, or even none. 
The objective of this study was to estimate the average annual cost in Italy incurred 
by the National Health Service (NHS) as well as society due to RVD in which there 
is an overexpression of VEGF. Methods: We developed a probabilistic incidence-
based cost of illness model to estimate an aggregate measure of the economic 
burden associated to RVD-induced diseases in terms of direct and indirect costs. A 
systematic literature review was performed in order to extrapolate epidemiological 
and direct cost data for total or partial blindness patient in Italy. Indirect costs were 
calculated as social security costs analyzing a specific database of the National 
Institute of Social Security (INPS). Data were analyzed considering the total services 
provided and the mean cost for two types of benefits: disability pension and attend-
ance allowance. Furthermore, one-way and probabilistic sensitivity analysis with 
5,000 Monte Carlo simulations was performed in order to test the robustness of 
results. Results: RVD with overexpression of VEGF was estimated to affect 0.84% 
of the Italian population (501.128). Direct costs analysis is under review while the 
annual indirect cost per patient for the disability pensions amount to € 3,454 for 
total blindness patient and € 3,157 for partial blindness. For attendance allowance 
was estimated an average cost of € 10,350 for total blindness € 2.397 for partial blind-
ness. ConClusions: This is the first study in which direct costs (incurred by NHS) 
and especially indirect costs (incurred by the Social Security System) were taken 
into account to estimate the overall burden associated with RVD with overexpres-
sion of VEGF in our Country.
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objeCtives: The objective of the study was to estimate the CoD in CRVO, in Turkish 
setting. Methods: An expert panel was held by participation of five ophthalmolo-
gists to discuss the disease management in CRVO. Physicians reviewed the literature, 
discussed the local clinical practices and all cost components; pharmaceuticals, 
treatment administration, monitoring and adverse events. Two different treatment 
options (ranibizumab and dexamethasone) were studied. September-2014 local 
prices for medications and procedures were used as sources. September-2014 EUR 
currency rate (2.8671TL/EUR) was used. Results: The frequency of treatments in a 
year were assumed as 8.8 and 2.0 and the numbers of outpatient visits in a year were 
accepted as 9 and 7 for ranibizumab and dexamethasone, respectively. Common 
adverse events were taken into account. The cost of cataract was accepted as equal 
to the cost of cataract removal operation which is 143EUR and the cost of retinal 
detachment was accepted as the average cost of surgical treatments as 368EUR. It 
was assumed that surgical treatment (trabeculectomy, Seton operation or cyclopho-
tocoagulation) was applied in 2% of increased ocular pressure (IOP) patients (average 
cost 183EUR/operation). Pharmacologic treatment was assumed to be applied in 98% 
of the IOP patients (4EUR/patient). Thus, overall cost of IOP was calculated as 7EUR. 
The total CoD was calculated as 3,823EUR per patients treated with ranibizumab, 
where the cost excluding pharmaceutical was determined as 138EUR. The CoD in 
patients treated with dexamethasone was estimated as 1,195EUR which is lower 
when compared to CoD in patients treated with ranibizumab. Total cost excluding 
pharmaceutical was calculated 240EUR for dexamethasone. ConClusions: In 
CRVO, the cost of treatment formed the major part of the total CoD when compared 
to monitoring, administration and adverse event costs.
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research the most accessible on costs and widespread technology of dental implan-
tation was conducted with zirconia or sandblasted/acid etched titanium implants 
despite their price is much higher than just titanium implants. Ukrainian patients 
pay out-of-pocket for dental implantation and the main task of stakeholders is to 
provide the most effective services. ConClusions: The most expensive was the 
implantation with sandblasted and acid etched titanium implants (p < 0,001) and 
zirconia implants (p < 0,5). Also we revealed that patients were highly motivated to 
pay for dental implantation in order to get the best esthetical result.
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objeCtives: The dental benefit of sugar free gum is scientifically proven. Comparing 
Germany and Finland, both countries show similar health systems as well as dental 
health among the population, but the consumption of sugar free gum is much higher 
in Finland. This paper aims at extrapolating the consumption of sugar free gum in 
Germany to values of Finland to estimate the potential costs savings for the German 
health care system due to a decreased risk of caries by consuming more sugar free 
gum. Methods: Overall dental costs in Germany are identified and the share of 
expenditures due to caries is estimated. The dental benefit of the consumption of 
sugar free gum is quantified as a reduction of the relative risk of caries based on data 
from the literature. Extrapolating the chewing frequencies in Germany to finish values 
and combining these with the dental benefit of consuming sugar free gum allows esti-
mating the potential cost saving due to better dental health for both the statutory and 
private health insurance. Results: The increase of the consumption of sugar free 
gum in Germany leads to a reduced risk for caries and better dental health. Potential 
cost saving amount to 240 M € for the statutory sector and 73 M € for the private 
sector. ConClusions: The overall state of dental health in Germany and Finland is 
similar and the countries show many commonalities with regard to the dental health 
system and overall dental health. By regularly consuming sugar free gum the risk 
of a caries can be reduced and cost savings up to 313 M € for Germany are possible.
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objeCtives: To analyse the direct and indirect medical costs in patients with dia-
betic macular oedema (DMO) or macular oedema secondary to retinal vein occlusion 
(MO-RVO). Methods: This was an observational, cross-sectional, multicenter study 
in adults diagnosed with DMO or MO-RVO in the last 6-12 months in one or both eyes. 
Health resource utilization (HRU) data were collected from diagnosis. Employment 
status of patients and the impact of the disease in their professional life were also 
assessed. Annual direct healthcare costs and indirect costs caused by morbidity were 
estimated by diagnostic group (€ , January 2014). Differences were assessed using 
Chi-square (or Fisher exact), Mann-Whitney or Kruskal-Wallis (Dunn contrast) tests. 
A multivariate regression analysis was used to predict the direct costs. Results: 
The study included 448 subjects (DMO n= 255; MO-RVO n= 193). No differences in age, 
gender or time of observation were found. There was stabilization over time in visual 
acuity and also a reduction in the foveal thickness. There were differences in diagnos-
tic costs: MO-RVO= € 1,856 (95%CI:1,741-1,971), bilateral DMO= € 1,661 (1,512-1,810) and 
unilateral DMO= € 1,401 (1,307-1,494), p< 0.001; and treatment costs (p< 0.001). There 
were also differences in total medical costs: MO-RVO= € 4,639 (3,809-5,469), bilateral 
DMO= € 6,275 (4,889-7,660) and unilateral DMO= € 6,269 (4,209-8,329), p< 0.001. Costs due 
to permanent disability were greater in bilateral DMO (€ 11,712, 95% CI 2,395-21,029) 
than in unilateral DMO (€ 4,284, −516-9,085) and MO-RVO (€ 1,052; −553-2,657), p< 0.05. 
In the regression analysis, the variables associated with health costs were: number 
of hospitalization days and number of visits, time of observation, diagnosis and days 
off work. ConClusions: Patients with bilateral DMO have higher direct healthcare 
costs and indirect costs due to morbidity.
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objeCtives: The objective of the study was to estimate the CoD in DME, in Turkish 
setting. Methods: A panel by participation of seven ophthalmologists was held 
to discuss the disease management in DME. Physicians reviewed the literature, 
discussed the local clinical practices and all cost components; pharmaceuticals, 
treatment administration, monitoring and adverse event. Cost of ranibizumab 
treatment was studied and January 2015 local prices for medications and proce-
dures were used as sources. January 2015 EUR currency rate (2.6785TL/EUR) was 
used. Results: The frequency of treatments and outpatient visits were assumed 
as 7.4 for the first year, 4.0 for the second year, 2.9 for the third year and 1.0 for 
the following years for ranibizumab. Common adverse events were taken into 
account. The cost of cataract was accepted as equal to the cost of cataract removal 
operation which is 153EUR. It was assumed that vitroretinal surgery was applied 
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objeCtives: Diabetic retinopathy/ DME are substantial complications leading to 
blindness. Ranibizumab (RBZ) 0.5mg and aflibercept (ABC) (anti-VEGF) change the 
DME-treatment paradigm. We estimated the cost-effectiveness of RBZ vs. ABC and 
laser from the Czech health care system perspective. Methods: A Markov cohort 
model with 8 health states (based on visual acuity) + dead in life-time horizon (3% 
discount rate) was used. Base-line patient characteristics came from the RESTORE 
study; 60% of patients were treated for their worse seeing-eye. Patients who were 
treated in both eyes were not included in the analysis. Transition probabilities (effi-
cacy) for the first 3 years of treatment for RBZ 0.5mg and laser were derived from 
RESTORE, for ABC from a published network meta-analysis (gain at least 10 letters: 
RBZ vs. ABC: OR = 1.59; 95%CrI 0.61 – 5.37). Natural progression of disease came 
from Wisconsin Epidemiologic Study. Utility for better and worse seeing-eye were 
derived from literature. RBZ and ABC dosing came from RESTORE (pro re nata, PRN) 
and from VIVID-DME, VISTA-DME study (bi-monthly after 5 initial monthly doses), 
respectively. Cost parity per dose of anti-VEGF (€ 855) was assumed. Results: Using 
a life-time horizon, total (discounted) costs and QALYs for RBZ, ABC, laser were 
:€ 7,110; € 9,562; € 1.490 and 7.589; 7.502; 7.022 QALYs, respectively. The incremental 
costs and QALYs for RBZ vs. laser were € 5.620 and 0.567 QALYs, with base-case ICER 
of 9.918 € /QALY. RBZ vs. ABC brought 0.087 QALY gain with € 2.452 savings, reflecting 
dominance of RBZ over ABC. According to probabilistic sensitivity analysis, there 
is 64%/ 90% probability that RBZ’s ICER is below 1GDP/ 3GDP per capita (€ 13,800/ 
€ 40,000) compared to laser. There is 62% probability that RBZ compared to ABC 
brings more QALY with lower costs. ConClusions: RBZ is dominant, cost-effective 
compared to ABC, laser approach, respectively in DME patients from the Czech 
health care system perspective.
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objeCtives: To evaluate the cost-effectiveness of intravitreal aflibercept (IVT-AFL) 
compared with ranibizumab in the management of patients with macular oedema 
secondary to branch retinal vein occlusion (BRVO). Methods: A 25-health-state 
Markov model considering ranges of visual acuity in both eyes was developed. 
Patients had a confirmed diagnosis of macular oedema secondary to BRVO and 
had best corrected visual acuity (BCVA) at baseline between 25 and 73 letters. The 
evaluation compared IVT-AFL 2mg with ranibizumab 0.5mg: the frequency of injec-
tions and monitoring were identical for both treatments, taken from randomised 
trials and a physician survey. A systematic review and indirect comparison were 
conducted to determine the probabilities of gaining at least 15 BCVA letters from 
baseline to 6 months; BCVA was then extrapolated over time to determine costs 
and outcomes. Utilities were taken from published literature and costs were esti-
mated from a UK payer perspective. Published drug prices were discounted to reflect 
patient access schemes. Costs and benefits were discounted at 3.5%. Results: The 
indirect comparison found that IVT-AFL was associated with a small numerical 
advantage in the likelihood of gaining 15 BCVA letters, compared with ranibizumab 
(median odds ratio = 1.08 95% Crl: 0.43-2.56). IVT-AFL was associated with a higher 
number of QALYs (0.045) per patient than ranibizumab. Both treatments are avail-
able to the National Health Service under confidential patient access schemes. Cost-
effectiveness was estimated for a range of possible discounts for each treatment. 
At price parity, IVT-AFL reduces cost by £4 per patient and was a dominant therapy. 
Resultswere sensitive to the unit cost of the drugs used, to comparative efficacy 
and number of injections for both treatments. ConClusions: IVT-AFL 2mg was 
found to offer greater QALYs and to be a cost-effective option when compared with 
ranibizumab 0.5mg in the management of macular oedema secondary to BRVO.
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objeCtives: This analysis assessed the value of apremilast in adult patients with 
moderate to severe chronic plaque psoriasis who have failed to respond to, have 
a contraindication to, or are intolerant to other systemic therapy in the Italian 
setting. Methods: A Markov state-transition cohort model was adapted to the 
Italian setting to compare costs and quality-adjusted life years (QALYs) from 2 
treatment sequences: apremilast, etanercept, adalimumab, ustekinumab, best sup-
portive care (BSC) vs. etanercept, adalimumab, ustekinumab, BSC. The time hori-
zon was 5 years, and a 28-day cycle was used. The National Health Service (NHS) 
perspective was chosen. Data on treatment efficacy (based on ≥ 75% improvement 
in Psoriasis Area and Severity Index [PASI-75] response rate) were taken from a 
network meta-analysis that included 22 clinical trials (2001-2013). Resource use 
and unit costs were taken from Italian standard sources. Frequency of screening 
and monitoring tests was obtained from real-world data (database analysis). Utility 
weights associated with PASI states were taken from a UK NHS health technology 
assessment appraisal. A 3% discount rate was applied to costs and benefits. Both 
deterministic and probabilistic sensitivity analyses were performed. Results: 
In the base case, the sequence including apremilast was dominant, with cost 
savings of € 1,169 (€ 57,965 vs. € 59,134) and 0.01 QALYs gained (3.96 vs. 3.95) over 5 
objeCtives: The objective was to estimate the CoD in wAMD, in Turkish set-
ting. Methods: An expert panel was held by participation of five ophthalmologists 
to discuss the disease management in wAMD. Physicians reviewed the literature, 
discussed the local clinical practices and all cost components; pharmaceuticals, 
treatment administration, monitoring, adverse events and blindness. The clinical/
economic parameters were entered as inputs of a Markov model mimicking the 
follow-up of patients up to 20 years. Cost of ranibizumab treatment was studied. 
September-2014 local prices for medications and procedures were used as sources. 
September-2014 EUR currency rate (2.8671TL/EUR) was used. Results: The fre-
quency of treatments and outpatient visits in a year were assumed as 12 for the 
first year and 6 for the second year. Fluorescein angiography was assumed to be 
performed every six months. Total cost of blindness was estimated as 2,964EUR/
year. The components of overall blindness cost include impairment salary in all 
(1,777EUR), home care services in 30% (990EUR), telescopic vision aid in one-thirds 
(96EUR), hip prosthesis operation, including prosthesis in 5% (64EUR), psychiatric 
management in 30% (32EUR) and visually impaired rehabilitation in 11% (6EUR). CoD 
calculation was started with the first implementation of treatment. The total cost 
for first year was 5,269EUR. The cost components included pharmaceutical costs 
(ranibizumab 4,915EUR), treatment administration (71-121EUR), monitoring (138-
208EUR), adverse events (0-2EUR) and blindness (23EUR). The average yearly costs 
(calculated according to the cumulative five and twenty-year costs) were 1,864EUR 
and 1,110EUR in patients treated with ranibizumab. ConClusions: The treatment 
cost formed the major part of the total CoD in the first year of treatment. With the 
increasing number of patients getting blind throughout the years, the cost of blind-
ness advanced to the first place.
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objeCtives: Published data regarding indirect (or work-related productivity) 
costs in psoriasis are limited. We sought to estimate indirect costs of moder-
ate-to-severe plaque psoriasis dependent on the level of psoriasis improvement 
(Psoriasis Activity Severity Index [PASI] change) due to treatment. Methods: 
Work Productivity and Activity Impairment Questionnaire Psoriasis (WPAI-PSO) 
data from a recent clinical trial (CLEAR) were analyzed by PASI change at 16 weeks. 
Using reported data for work impairment due to psoriasis for trial subjects who 
were employed at baseline and data from national employment averages (full- vs. 
part-time employment, work hours/week, hourly wages), we estimated weekly 
and annual indirect costs by PASI change for moderate-to-severe plaque pso-
riasis patients in Germany. Results: Overall work impairment due to psoriasis 
decreased with greater skin clearance (PASI change < 50= 23.8%, 50-74= 13.3%, 
75-89= 6.4%, ≥ 90= 4.9%), with the majority of impairment being related to produc-
tivity loss at work (presenteeism) rather than absenteeism. On average, patients 
working with poorly controlled (PASI change < 50) moderate-to-severe psoriasis 
lost > 8 hours a week of productive work time due to psoriasis symptoms; while 
productivity loss for patients with high clearance (PASI change ≥ 90) was small (< 2 
hours/week). From a societal perspective (includes patients not working), indirect 
costs per patient per week were estimated to be € 117 for PASI change < 50, € 68 for 
50-74, € 33 for 75-89, and € 25 for ≥ 90. Restricting the population to those employed 
at baseline (employer’s perspective), indirect costs per employed patient per week 
decreased from € 174 (PASI change < 50) to € 38 (PASI change ≥ 90). Annual indirect 
costs from the societal perspective decreased from € 6,080 (PASI change < 50) to 
€ 1,316 (PASI change ≥ 90) per patient. ConClusions: Based on our estimates, PASI 
improvement of ≥ 90 is linked to a prominent increase in workplace productivity 
and reduction in indirect costs in moderate-to-severe psoriasis patients from both 
the societal and employer perspectives.
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objeCtives: To determine the direct costs associated with high myopia (HM) 
patients with and without choroidal neovascularisation (mCNV). Methods: 
Observational, retrospective, multicentre study in adult patients selected consecu-
tively with HM with/without mCNV. The patient characteristics, clinical course and 
use of health resources were recorded. Patients reported the use of assistive devices 
and employment status from diagnosis. Annual direct medical costs (AMC, from 
the perspective of the National Health System) and direct non-medical costs were 
estimated (AnMC) [€ , January 2014]. Differences were assessed using Chi-square 
(or Fisher exact), Mann-Whitney or Kruskal-Wallis (Bonferroni contrast) tests. A 
multivariate regression analysis was done (General Linear Model, GLM). Results: A 
total of 137 mCNV and 48 HM patients were included (mean of age±SD: 55.1±12.8 vs. 
54.7±13.8 years, respectively; p= 0.2). 80% were women in both groups. The observa-
tion time ranged from 17.9±9.6 to 20.0±9.7 months in mCNV and from 47.1±21.5 to 
45.5±20.7 months in HM. In mCNV patients, a greater need for visits to the emer-
gency room (41.7% vs. 25%; p= 0.06) and retinal specialists (91.2% vs. 77.1%; p= 0.01) 
was found. The AMC was higher in mCNV patients 1,985 € (95% CI 1,772-2,198) vs. 356 
€ (251-480), p< 0.001. The AnMC was also higher in mCNV patients 256 € (11-524) vs. 
19 € (11-26); p> 0.4. Healthcare costs were not homogeneous in all geographic areas 
(p= 0.002). The number of affected eyes, the follow-up time and mCNV were factors 
associated to the direct cost (according to the GLM). The impact on job performance 
was higher in mCNV vs. HM (fairly or very affected) 27.7% vs. 10.4%. ConClusions: 
The mCNV implies higher health costs than HM. Moreover, mCNV patients have a 
greater need of care and assistive devices, and a greater impact on their working life.
